These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22289279)

  • 1. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
    Athanasakis K; Fragoulakis V; Tsiantou V; Masaoutis P; Maniadakis N; Kyriopoulos J
    Clin Ther; 2012 Feb; 34(2):446-56. PubMed ID: 22289279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR; Moride Y; Rochon S
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
    Colquitt JL; Jones J; Tan SC; Takeda A; Clegg AJ; Price A
    Health Technol Assess; 2008 May; 12(16):iii-iv, ix-201. PubMed ID: 18462575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
    Gower EW; Cassard SD; Bass EB; Schein OD; Bressler NM
    Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
    Wolowacz SE; Roskell N; Kelly S; Maciver FM; Brand CS
    Pharmacoeconomics; 2007; 25(10):863-79. PubMed ID: 17887807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice.
    Studnička J; Říhová B; Rencová E; Rozsíval P; Dubská Z; Chrapek O; Kolář P; Kandrnal V; Demlová R; Pitrová Š; Řehák J
    Ophthalmologica; 2013; 230(1):34-42. PubMed ID: 23751929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.
    Javitt JC; Zlateva GP; Earnshaw SR; Pleil AM; Graham CN; Brogan AJ; Shah SN; Adamis AP
    Value Health; 2008; 11(4):563-74. PubMed ID: 18179676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese].
    Yanagi Y; Aihara Y; Fukuda T; Hashimoto H
    Nippon Ganka Gakkai Zasshi; 2011 Sep; 115(9):825-31. PubMed ID: 22073599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
    Brown GC; Brown MM; Brown HC; Kindermann S; Sharma S
    Ophthalmology; 2007 Jun; 114(6):1170-8. PubMed ID: 17320964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
    Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.
    Vedula SS; Krzystolik MG
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005139. PubMed ID: 18425911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Sharma S; Brown GC; Brown MM; Hollands H; Shah GK
    Ophthalmology; 2001 Nov; 108(11):2051-9. PubMed ID: 11713079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC; Lade RJ; Adewoyin T; Chong NV
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.
    Grieve R; Guerriero C; Walker J; Tomlin K; Langham J; Harding S; Chakravathy U; Carpenter J; Reeves BC;
    Ophthalmology; 2009 Dec; 116(12):2471-77.e1-2. PubMed ID: 19948278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC; Brown MM; Turpcu A; Rajput Y
    Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
    Takeda AL; Colquitt J; Clegg AJ; Jones J
    Br J Ophthalmol; 2007 Sep; 91(9):1177-82. PubMed ID: 17475698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.